2014 Form 10-K Financial Statement
#000114420414058454 Filed on September 29, 2014
Income Statement
| Concept | 2014 | 2013 Q2 | 2013 |
|---|---|---|---|
| Revenue | $205.0K | $620.0K | $1.007M |
| YoY Change | -79.64% | 77.14% | -21.14% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.840M | $950.0K | $3.910M |
| YoY Change | -1.79% | -30.15% | -26.23% |
| % of Gross Profit | |||
| Research & Development | $1.898M | $970.0K | $3.431M |
| YoY Change | -44.68% | -7.62% | -31.12% |
| % of Gross Profit | |||
| Depreciation & Amortization | $3.000K | $90.00K | $2.000K |
| YoY Change | 50.0% | 0.0% | -71.43% |
| % of Gross Profit | |||
| Operating Expenses | $4.045M | $1.920M | $7.674M |
| YoY Change | -47.29% | -23.2% | -27.63% |
| Operating Profit | -$3.840M | -$6.667M | |
| YoY Change | -42.4% | -28.52% | |
| Interest Expense | $0.00 | -$20.00K | $90.00K |
| YoY Change | -100.0% | -102.56% | 42.86% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $174.0K | $10.00K | $469.0K |
| YoY Change | -62.9% | ||
| Pretax Income | -$3.670M | -$1.320M | -$6.200M |
| YoY Change | -40.81% | -2.94% | 9.15% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$3.666M | -$1.320M | -$6.198M |
| YoY Change | -40.85% | -2.94% | 9.2% |
| Net Earnings / Revenue | -1788.29% | -212.9% | -615.49% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$582.5K | -$243.5K | -$1.255M |
| COMMON SHARES | |||
| Basic Shares Outstanding | |||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 | 2013 Q2 | 2013 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.590M | $4.410M | $4.410M |
| YoY Change | -18.59% | -21.53% | -21.53% |
| Cash & Equivalents | $4.414M | ||
| Short-Term Investments | |||
| Other Short-Term Assets | $120.0K | $31.00K | $1.210M |
| YoY Change | -90.08% | -95.87% | 61.33% |
| Inventory | |||
| Prepaid Expenses | $31.00K | ||
| Receivables | $210.0K | $1.007M | $1.010M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $3.910M | $6.635M | $6.640M |
| YoY Change | -41.11% | -3.84% | -3.77% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $10.00K | $6.000K | $10.00K |
| YoY Change | 0.0% | 100.0% | |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $2.713M | ||
| YoY Change | -5.21% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $2.580M | $2.719M | $2.710M |
| YoY Change | -4.8% | -5.1% | -5.57% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $3.910M | $6.635M | $6.640M |
| Total Long-Term Assets | $2.580M | $2.719M | $2.710M |
| Total Assets | $6.490M | $9.354M | $9.350M |
| YoY Change | -30.59% | -4.21% | -4.3% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $300.0K | $2.401M | $2.400M |
| YoY Change | -87.5% | -15.64% | -15.79% |
| Accrued Expenses | $100.0K | $1.885M | $1.890M |
| YoY Change | -94.71% | 719.57% | 721.74% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $400.0K | $4.286M | $4.290M |
| YoY Change | -90.68% | 19.19% | 19.17% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $400.0K | $4.286M | $4.290M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $400.0K | $4.290M | $4.290M |
| YoY Change | -90.68% | 19.17% | 19.17% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$37.54M | ||
| YoY Change | 19.78% | ||
| Common Stock | $42.60M | ||
| YoY Change | 13.59% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $6.100M | $5.068M | $5.070M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $6.490M | $9.354M | $9.350M |
| YoY Change | -30.59% | -4.21% | -4.3% |
Cashflow Statement
| Concept | 2014 | 2013 Q2 | 2013 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$3.666M | -$1.320M | -$6.198M |
| YoY Change | -40.85% | -2.94% | 9.2% |
| Depreciation, Depletion And Amortization | $3.000K | $90.00K | $2.000K |
| YoY Change | 50.0% | 0.0% | -71.43% |
| Cash From Operating Activities | -$4.120M | -$910.0K | -$4.849M |
| YoY Change | -15.03% | -12.5% | -19.32% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $4.000K | -$40.00K | $7.000K |
| YoY Change | -42.86% | -33.33% | 600.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$260.0K | -$40.00K | -$195.0K |
| YoY Change | 33.33% | -33.33% | -20.41% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $480.0K | $4.284M | |
| YoY Change | -88.8% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 3.550M | 3.830M | $3.834M |
| YoY Change | -7.41% | -57.57% | |
| NET CHANGE | |||
| Cash From Operating Activities | -4.120M | -910.0K | -$4.849M |
| Cash From Investing Activities | -260.0K | -40.00K | -$195.0K |
| Cash From Financing Activities | 3.550M | 3.830M | $3.834M |
| Net Change In Cash | -830.0K | 2.880M | -$1.210M |
| YoY Change | -31.4% | -361.82% | -143.51% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$4.120M | -$910.0K | -$4.849M |
| Capital Expenditures | $4.000K | -$40.00K | $7.000K |
| Free Cash Flow | -$4.124M | -$870.0K | -$4.856M |
| YoY Change | -15.07% | -11.22% | -19.21% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | pure |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
4969000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5168000 | USD |
| CY2013Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2256000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
2593000 | USD |
| CY2014 | ibio |
Long Term Purchase Commitment Expire Date
LongTermPurchaseCommitmentExpireDate
|
2015-12-31 | |
| CY2013Q2 | us-gaap |
Share Price
SharePrice
|
0.42 | |
| CY2013 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0004 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.979 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P2M12D | |
| CY2013Q2 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
0 | USD |
| CY2012Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
20940796 | shares |
| CY2013Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
25395940 | shares |
| CY2014 | ibio |
Class Of Warrants Or Rights Exercised
ClassOfWarrantsOrRightsExercised
|
7750000 | shares |
| CY2014 | ibio |
Class Of Warrants Or Rights Expired
ClassOfWarrantsOrRightsExpired
|
8876029 | shares |
| CY2014Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
8769911 | shares |
| CY2014Q2 | ibio |
Class Of Warrants Or Right Exercisable
ClassOfWarrantsOrRightExercisable
|
8769911 | shares |
| CY2014 | ibio |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
|
0.40 | |
| CY2014 | ibio |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
|
1.18 | |
| CY2014Q2 | ibio |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable
|
1.38 | |
| CY2013Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
10000000 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
15000000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
|
175000000 | shares |
| CY2013Q4 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
7750000 | shares |
| CY2013Q4 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
3100000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6198000 | USD |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3666000 | USD |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
49381000 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
62968000 | shares |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.13 | |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
| CY2013 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
6700000 | shares |
| CY2014 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
8500000 | shares |
| CY2013 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
25400000 | shares |
| CY2014 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
8800000 | shares |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1263000 | USD |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1075000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1007000 | USD |
| CY2014 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
205000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3431000 | USD |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1898000 | USD |
| CY2013 | ibio |
Research And Development Expense Effect Of Settlement Agreement
ResearchAndDevelopmentExpenseEffectOfSettlementAgreement
|
0 | USD |
| CY2014 | ibio |
Research And Development Expense Effect Of Settlement Agreement
ResearchAndDevelopmentExpenseEffectOfSettlementAgreement
|
-1041000 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4243000 | USD |
| CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3888000 | USD |
| CY2013 | ibio |
General And Administrative Expense Effect Of Settlement Agreement
GeneralAndAdministrativeExpenseEffectOfSettlementAgreement
|
0 | USD |
| CY2014 | ibio |
General And Administrative Expense Effect Of Settlement Agreement
GeneralAndAdministrativeExpenseEffectOfSettlementAgreement
|
-700000 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
7674000 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
4045000 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
90000 | USD |
| CY2014 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2013 | ibio |
Interest Expense Effect Of Settlement Agreement
InterestExpenseEffectOfSettlementAgreement
|
0 | USD |
| CY2014 | ibio |
Interest Expense Effect Of Settlement Agreement
InterestExpenseEffectOfSettlementAgreement
|
-122000 | USD |
| CY2014 | us-gaap |
Royalty Income Nonoperating
RoyaltyIncomeNonoperating
|
42000 | USD |
| CY2013 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-4000 | USD |
| CY2014 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3000 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2013 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
520000 | USD |
| CY2014 | us-gaap |
Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
|
0 | USD |
| CY2013 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
469000 | USD |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
174000 | USD |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5510000 | shares |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6760000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1330000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1990000 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8483334 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
8396500 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5288542 | shares |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.56 | |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.45 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.02 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0.47 | |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.25 | |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
1.25 | |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.48 | |
| CY2012 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y1M6D | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y6M | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y2M12D | |
| CY2012Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
494000 | USD |
| CY2013Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
161000 | USD |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
178000 | USD |
| CY2014Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
161000 | USD |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
6500000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.90 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.40 | |
| CY2014Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
1400000 | USD |
| CY2014 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y4M24D | |
| CY2012Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6169000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
480000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
29000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1263000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1075000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
71000 | USD |
| CY2013 | ibio |
Effect Of Settlement Agreement
EffectOfSettlementAgreement
|
0 | USD |
| CY2014 | ibio |
Effect Of Settlement Agreement
EffectOfSettlementAgreement
|
1863000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1263000 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1075000 | USD |
| CY2013 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
336000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
2000 | USD |
| CY2014 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
358000 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
3000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4849000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4116000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
188000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
255000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
4000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-195000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-259000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4284000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
480000 | USD |
| CY2013 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
0 | USD |
| CY2014 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
3100000 | USD |
| CY2013 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
450000 | USD |
| CY2014 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
29000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3834000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
3551000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-1210000 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-824000 | USD |
| CY2012Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5624000 | USD |
| CY2013 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
0 | USD |
| CY2014 | ibio |
Unpaid Intangible Assets Included In Accounts Payable
UnpaidIntangibleAssetsIncludedInAccountsPayable
|
12000 | USD |
| CY2013 | ibio |
Unpaid Intangible Assets Included In Accrued Expenses
UnpaidIntangibleAssetsIncludedInAccruedExpenses
|
0 | USD |
| CY2014 | ibio |
Unpaid Intangible Assets Included In Accrued Expenses
UnpaidIntangibleAssetsIncludedInAccruedExpenses
|
20000 | USD |
| CY2014 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>1.</b></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><b>Nature of Business</b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on the commercialization of its proprietary plant-based protein expression technologies - the iBioLaunch™ platform for vaccines and therapeutic proteins and the iBioModulator™ platform for vaccine enhancement – and on developing and commercializing select biopharmaceutical product candidates. The advantages of iBio’s technology include the ability to manufacture therapeutic proteins that are difficult or commercially infeasible to produce with conventional methods, and reduced production time, capital and operating costs for biopharmaceuticals. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company has two wholly-owned subsidiaries, iBioDefense Biologics LLC (“iBioDefense”), a Delaware limited liability company formed in July 2013 to explore development and commercialization of defense-specific applications of the Company’s proprietary technology, and iBio Peptide Therapeutics LLC, a Delaware limited liability company formed in November 2013 to explore development and commercialization of plant based peptide for the treatment of Fibrosis. Additionally the Company has a 99% interest in a subsidiary organized in Brazil, iBIO DO BRASIL BIOFARMACÊUTICA LTDA. (“iBio Brazil”), to manage and expand the Company’s business activities in Brazil. The activities of iBio Brazil are intended to include coordination and expansion of the Company’s existing relationship with FioCruz (part of the Ministry of Health of Brazil) beyond the current Yellow Fever Vaccine program and development of biosimilar products with private sector participants for the Brazilian market. The subsidiaries have not conducted any activity through June 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-06-30 | |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
iBio, Inc. | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001420720 | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2013Q4 | dei |
Entity Public Float
EntityPublicFloat
|
11540000 | USD |
| CY2014 | dei |
Trading Symbol
TradingSymbol
|
IBIO | |
| CY2014Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
67460267 | shares |
| CY2013 | ibio |
Research And Development Effect Of Amendment To Collaboration And License Agreement
ResearchAndDevelopmentEffectOfAmendmentToCollaborationAndLicenseAgreement
|
0 | USD |
| CY2014 | ibio |
Research And Development Effect Of Amendment To Collaboration And License Agreement
ResearchAndDevelopmentEffectOfAmendmentToCollaborationAndLicenseAgreement
|
-1007000 | USD |
| CY2012Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.39 | |
| CY2013 | ibio |
Reversal Of Accrued Warrants
ReversalOfAccruedWarrants
|
0 | USD |
| CY2014 | ibio |
Reversal Of Accrued Warrants
ReversalOfAccruedWarrants
|
71000 | USD |
| CY2013Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.23 | |
| CY2013 | ibio |
General And Administrative Effect Of Amendment To Collaboration And License Agreement
GeneralAndAdministrativeEffectOfAmendmentToCollaborationAndLicenseAgreement
|
0 | USD |
| CY2014 | ibio |
General And Administrative Effect Of Amendment To Collaboration And License Agreement
GeneralAndAdministrativeEffectOfAmendmentToCollaborationAndLicenseAgreement
|
1007000 | USD |
| CY2014Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.38 | |
| CY2013 | us-gaap |
Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
|
-3000 | USD |
| CY2014 | us-gaap |
Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
|
-56000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3834000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3100000 | USD |
| CY2013 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-2447000 | USD |
| CY2014 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-1267000 | USD |
| CY2013 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-366000 | USD |
| CY2014 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-215000 | USD |
| CY2013 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
-2813000 | USD |
| CY2014 | ibio |
Current And Deferred Federal And State Taxes
CurrentAndDeferredFederalAndStateTaxes
|
-1482000 | USD |
| CY2013 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
-2813000 | USD |
| CY2014 | ibio |
Income Tax Expense Benefit Valuation Allowance
IncomeTaxExpenseBenefitValuationAllowance
|
-1482000 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | ibio |
Effect Of Amendment To Collaboration And License Agreement On Accounts Receivable And Accounts Payable
EffectOfAmendmentToCollaborationAndLicenseAgreementOnAccountsReceivableAndAccountsPayable
|
0 | USD |
| CY2014 | ibio |
Effect Of Amendment To Collaboration And License Agreement On Accounts Receivable And Accounts Payable
EffectOfAmendmentToCollaborationAndLicenseAgreementOnAccountsReceivableAndAccountsPayable
|
1007000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
10856000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11954000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3198000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
3626000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
737000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
764000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
56000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
122000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
18000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
|
13000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
14753000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
16235000 | USD |
| CY2013Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | USD |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.34 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.06 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.03 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.04 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.01 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.02 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.45 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.41 | pure |
| CY2013 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2014 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | pure |
| CY2008Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
5500000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
|
31600000 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
|
20400000 | USD |
| CY2013 | us-gaap |
Derivative Gain On Derivative
DerivativeGainOnDerivative
|
500000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
360000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
346000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
332000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
305000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
270000 | USD |
| CY2014Q2 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
962000 | USD |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
80000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
266666 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
1.55 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0.62 | |
| CY2014 | us-gaap |
Legal Fees
LegalFees
|
121000 | USD |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
179000 | USD |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
2500000 | USD |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1100000 | USD |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P9Y | |
| CY2013Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
77000 | USD |
| CY2014Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
110000 | USD |
| CY2013Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
31000 | USD |
| CY2014Q2 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
8000 | USD |
| CY2013Q2 | ibio |
Prepaid Expenses Research And Development Costs
PrepaidExpensesResearchAndDevelopmentCosts
|
106000 | USD |
| CY2014Q2 | ibio |
Prepaid Expenses Research And Development Costs
PrepaidExpensesResearchAndDevelopmentCosts
|
0 | USD |
| CY2013Q2 | ibio |
Prepaid Expenses Semi Annual Tta Payments
PrepaidExpensesSemiAnnualTtaPayments
|
1000000 | USD |
| CY2014Q2 | ibio |
Prepaid Expenses Semi Annual Tta Payments
PrepaidExpensesSemiAnnualTtaPayments
|
0 | USD |
| CY2013Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
93000 | USD |
| CY2014Q2 | us-gaap |
Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
|
38000 | USD |
| CY2014 | ibio |
Cash Based Compensation
CashBasedCompensation
|
10000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
656000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
205000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
289000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-97000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-445000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
56000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1655000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-28000 | USD |
| CY2014Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
12600000 | USD |
